ALCAM and neoplasm: To study the tumor targeting performance of CX-2009, biodistribution studies with 10, 110, and 510 μg of [89Zr]Zr-CX-2009 were performed in CD166-expressing H292 tumor-bearing mice at 72 h p.i. It is well known from biodistribution studies with conventional antibodies that the level of tumor uptake is dependent on the antibody dose as well as on the expression level of the target antigen in tumor and healthy tissues.